期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Peptide vaccine against glioblastoma:from bench to bedside
1
作者 Tianrui Yang Yixin Shi +4 位作者 Tingyu Liang Hao Xing Wenbin Ma Yan Michael Li Yu Wang 《Holistic Integrative Oncology》 2022年第1期280-291,共12页
Glioblastoma accounts for almost half of all intracranial primary malignancies and has the worst prognosis.Because of its high malignancy and frequent recurrence after standard therapy,it is of great signifcance to ex... Glioblastoma accounts for almost half of all intracranial primary malignancies and has the worst prognosis.Because of its high malignancy and frequent recurrence after standard therapy,it is of great signifcance to explore new therapy options.Recently immune therapy has taken remarkable progress in a variety of tumors,among which peptide vaccines utilize peptide sequences based on tumor-specifc antigens or tumor-associated antigen targets to activate selfimmune response against tumor cells.However,due to the particularity of intracranial central nervous system tumors,the application of peptide vaccines in glioblastoma still faces challenges.This article mainly reviews the immune basis and important clinical trial results of peptide vaccine therapy for GBM,analyzes the reasons for its poor efcacy,and proposes the development direction of peptide vaccines for the unique challenges of immunotherapy in GBM.An in-depth understanding and elaboration of the application and related issues of peptide vaccine in the treatment of GBM will help to formulate relevant treatment strategies in future clinical and basic research. 展开更多
关键词 GLIOBLASTOMA Immune microenvironment Peptide vaccines Clinical trials
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部